3 medical devices ‘stars’
Here are three smaller companies on the ASK that are advancing their device products in a very promising manner and hoping to emulate the examples of Cochlear and ResMed.
James Dunn is a freelance finance journalist and media consultant. James was founding editor of Shares magazine, and formerly, the personal investment editor at The Australian. His first book, Share Investing for Dummies, was published by John Wiley & Co. in September 2002: a second edition was published in March 2007, and a third edition was published in April 2011. There have also been two editions of the mini-version, Getting Started in Shares for Dummies. James is also a regular finance commentator on Australian radio and television: he gives a daily finance report on Radio 3AW in Melbourne and is a weekly commentator on Sky Business.
Here are three smaller companies on the ASK that are advancing their device products in a very promising manner and hoping to emulate the examples of Cochlear and ResMed.
Here are three non-Australian ASX-listed software providers whose products are used all over the world.
Like a number of similar companies, Atlassian has huge total addressable markets to grow into, and large material upside possible. Here’s my view on this company listed on the NASDAQ but founded by two Australians.
In my experience over years of writing in this area, every investor is looking for cheap stocks. Today I’ve come up with three that I think fit that description.
Here are three stocks on the verge of making the magical 100-cent milestone and are poised to head higher.
Here are two small gold stocks that look like good buying opportunities for those comfortable with the potential swings of resource stocks.
Commodities are positioned for a huge surge. Here are three of the ASX-listed companies that, in the words of the old cliché, make money by “selling shovels to the miners” – or the drillers.
For risk takers, here are two biotech stars in the making
Australians were already shopping online before being locked-up during COVID, but the pandemic gave laptop retail therapy a boost; at least partially, because people were bored.
Although coal prices have come down, the longer term outlook remains strong. Here are the three best coal investment on the ASX right now.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.